NCT01237223
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
See it on ClinicalTrials.gov ↗944 people
30.5%
69.5%
288 womenmiddle line = equal numbers656 men
- Phase
- PHASE3
- Paid for by
- Novartis
- Finished
- 2011-05
- Health conditions
- Essential Hypertension
- Who could join
- Anyone
- Ages
- 20 Years – no maximum
- Average age
- mean 55.1 years
- Age 65+
- 18.9%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.